• linkedin
  • Increase Font
  • Sharebar

    Novel agent may protect against major UTI pathogen

    In the search for new ways to combat urinary tract infections, researchers have shown that an experimental drug that stabilizes a protein called HIF-1alpha protects human bladder cells and mice against a major UTI pathogen.

    ALSO SEE: Extended antimicrobial prophylaxis raises C. diff risk

    The drug may eventually provide a therapeutic alternative or complement to standard antibiotic treatment, say study authors from the University of California, San Diego School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences.

    The study was published online in by PLOS Pathogens (April 30, 2015).

    HIF-1alpha is known to influence the innate immune response, researchers say. Like many regulator proteins, HIF-1alpha is relatively short-lived. To increase HIF-1alpha levels, researchers have developed drugs that delay its breakdown. This same pathway has been the target for drugs now in advanced clinical trials for treatment of anemia.

    READ: Are you satisifed with local infection prevention protocols?

    In the current study, lead author Victor Nizet, MD, and colleagues explored the use of HIF-1alpha-stabilizing drugs to boost the innate immune response to uropathogenic Escherichia coli (UPEC) bacteria, a major cause of UTIs. In healthy human urinary tract cells, treatment with the drugs increased HIF-1alpha levels. Such cells were then more resistant to UPEC attachment, invasion, and killing than human urinary tract cells with normal HIF-1alpha levels, Dr. Nizet’s team said in a University of California, San Diego news release.

    NEXT: HIF-1alpha stabilizers protected against UPEC infection

    More from Urology Times

    Injected TRT earns high marks for safety, effectiveness

    New Products: Handheld bladder scanner, T nasal gel, and more

    Good riddance, SGR: Urology groups, others react

    Richard R. Kerr
    Kerr is group content director for Urology Times.


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available